Cargando…

Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and Alprazolam following insulin-induced hypoglycemia in humans

RATIONALE: The orexin-hypocretin system is important for translating peripheral metabolic signals and central neuronal inputs to a diverse range of behaviors, from feeding, motivation and arousal, to sleep and wakefulness. Orexin signaling is thus an exciting potential therapeutic target for disorde...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Ameera X., Miller, Sam R., Nathan, Pradeep J., Kanakaraj, Ponmani, Napolitano, Antonella, Lawrence, Philip, Koch, Annelize, Bullmore, Edward T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159598/
https://www.ncbi.nlm.nih.gov/pubmed/24770625
http://dx.doi.org/10.1007/s00213-014-3520-7
_version_ 1782334259709607936
author Patel, Ameera X.
Miller, Sam R.
Nathan, Pradeep J.
Kanakaraj, Ponmani
Napolitano, Antonella
Lawrence, Philip
Koch, Annelize
Bullmore, Edward T.
author_facet Patel, Ameera X.
Miller, Sam R.
Nathan, Pradeep J.
Kanakaraj, Ponmani
Napolitano, Antonella
Lawrence, Philip
Koch, Annelize
Bullmore, Edward T.
author_sort Patel, Ameera X.
collection PubMed
description RATIONALE: The orexin-hypocretin system is important for translating peripheral metabolic signals and central neuronal inputs to a diverse range of behaviors, from feeding, motivation and arousal, to sleep and wakefulness. Orexin signaling is thus an exciting potential therapeutic target for disorders of sleep, feeding, addiction, and stress. OBJECTIVES/METHODS: Here, we investigated the low dose pharmacology of orexin receptor antagonist, SB-649868, on neuroendocrine, sympathetic nervous system, and behavioral responses to insulin-induced hypoglycemic stress, in 24 healthy male subjects (aged 18–45 years; BMI 19.0–25.9 kg/m(2)), using a randomized, double-blind, placebo-controlled, within-subject crossover design. Alprazolam, a licensed benzodiazepine anxiolytic, was used as a positive comparator, as it has previously been validated using the insulin tolerance test (ITT) model in humans. RESULTS: Of the primary endpoints, ITT induced defined increases in pulse rate, plasma cortisol, and adrenocorticotropic hormone in the placebo condition, but these responses were not significantly impacted by alprazolam or SB-649868 pre-treatment. Of the secondary endpoints, ITT induced a defined increase in plasma concentrations of adrenaline, noradrenaline, growth hormone (GH), and prolactin in the placebo condition. Alprazolam pre-treatment significantly reduced the GH response to ITT (p < 0.003), the peak electromyography (p < 0.0001) and galvanic skin response (GSR, p = 0.04) to acoustic startle, the resting GSR (p = 0.01), and increased appetite following ITT (p < 0.0005). SB-649868 pre-treatment produced no significant results. CONCLUSION: We concluded that the ITT model may be informative for assessing the effects of drugs directly acting on the neuroendocrine or sympathetic nervous systems, but could not be validated for studying low dose orexin antagonist activity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00213-014-3520-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4159598
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-41595982014-09-11 Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and Alprazolam following insulin-induced hypoglycemia in humans Patel, Ameera X. Miller, Sam R. Nathan, Pradeep J. Kanakaraj, Ponmani Napolitano, Antonella Lawrence, Philip Koch, Annelize Bullmore, Edward T. Psychopharmacology (Berl) Original Investigation RATIONALE: The orexin-hypocretin system is important for translating peripheral metabolic signals and central neuronal inputs to a diverse range of behaviors, from feeding, motivation and arousal, to sleep and wakefulness. Orexin signaling is thus an exciting potential therapeutic target for disorders of sleep, feeding, addiction, and stress. OBJECTIVES/METHODS: Here, we investigated the low dose pharmacology of orexin receptor antagonist, SB-649868, on neuroendocrine, sympathetic nervous system, and behavioral responses to insulin-induced hypoglycemic stress, in 24 healthy male subjects (aged 18–45 years; BMI 19.0–25.9 kg/m(2)), using a randomized, double-blind, placebo-controlled, within-subject crossover design. Alprazolam, a licensed benzodiazepine anxiolytic, was used as a positive comparator, as it has previously been validated using the insulin tolerance test (ITT) model in humans. RESULTS: Of the primary endpoints, ITT induced defined increases in pulse rate, plasma cortisol, and adrenocorticotropic hormone in the placebo condition, but these responses were not significantly impacted by alprazolam or SB-649868 pre-treatment. Of the secondary endpoints, ITT induced a defined increase in plasma concentrations of adrenaline, noradrenaline, growth hormone (GH), and prolactin in the placebo condition. Alprazolam pre-treatment significantly reduced the GH response to ITT (p < 0.003), the peak electromyography (p < 0.0001) and galvanic skin response (GSR, p = 0.04) to acoustic startle, the resting GSR (p = 0.01), and increased appetite following ITT (p < 0.0005). SB-649868 pre-treatment produced no significant results. CONCLUSION: We concluded that the ITT model may be informative for assessing the effects of drugs directly acting on the neuroendocrine or sympathetic nervous systems, but could not be validated for studying low dose orexin antagonist activity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00213-014-3520-7) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2014-04-26 2014 /pmc/articles/PMC4159598/ /pubmed/24770625 http://dx.doi.org/10.1007/s00213-014-3520-7 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Investigation
Patel, Ameera X.
Miller, Sam R.
Nathan, Pradeep J.
Kanakaraj, Ponmani
Napolitano, Antonella
Lawrence, Philip
Koch, Annelize
Bullmore, Edward T.
Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and Alprazolam following insulin-induced hypoglycemia in humans
title Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and Alprazolam following insulin-induced hypoglycemia in humans
title_full Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and Alprazolam following insulin-induced hypoglycemia in humans
title_fullStr Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and Alprazolam following insulin-induced hypoglycemia in humans
title_full_unstemmed Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and Alprazolam following insulin-induced hypoglycemia in humans
title_short Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and Alprazolam following insulin-induced hypoglycemia in humans
title_sort neuroendocrine and sympathetic responses to an orexin receptor antagonist, sb-649868, and alprazolam following insulin-induced hypoglycemia in humans
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159598/
https://www.ncbi.nlm.nih.gov/pubmed/24770625
http://dx.doi.org/10.1007/s00213-014-3520-7
work_keys_str_mv AT patelameerax neuroendocrineandsympatheticresponsestoanorexinreceptorantagonistsb649868andalprazolamfollowinginsulininducedhypoglycemiainhumans
AT millersamr neuroendocrineandsympatheticresponsestoanorexinreceptorantagonistsb649868andalprazolamfollowinginsulininducedhypoglycemiainhumans
AT nathanpradeepj neuroendocrineandsympatheticresponsestoanorexinreceptorantagonistsb649868andalprazolamfollowinginsulininducedhypoglycemiainhumans
AT kanakarajponmani neuroendocrineandsympatheticresponsestoanorexinreceptorantagonistsb649868andalprazolamfollowinginsulininducedhypoglycemiainhumans
AT napolitanoantonella neuroendocrineandsympatheticresponsestoanorexinreceptorantagonistsb649868andalprazolamfollowinginsulininducedhypoglycemiainhumans
AT lawrencephilip neuroendocrineandsympatheticresponsestoanorexinreceptorantagonistsb649868andalprazolamfollowinginsulininducedhypoglycemiainhumans
AT kochannelize neuroendocrineandsympatheticresponsestoanorexinreceptorantagonistsb649868andalprazolamfollowinginsulininducedhypoglycemiainhumans
AT bullmoreedwardt neuroendocrineandsympatheticresponsestoanorexinreceptorantagonistsb649868andalprazolamfollowinginsulininducedhypoglycemiainhumans